- Top of page
- Conflict of Interest
Aim: To evaluate the safety and efficacy of lamotrigine monotherapy as an acute treatment of bipolar mood elevation in children with bipolar spectrum disorders. Method: This was a 12-week, open-label, prospective trial of lamotrigine monotherapy to assess the effectiveness and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Improvement scale (CGI-I), Children's Depression Rating Scale (CDRS), and Brief Psychiatric Rating Scale (BPRS). Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis. Results: Thirty-nine children with bipolar disorder (YMRS at entry: 31.6 ± 5.5) were enrolled in the study and 22 (56%) completed the 12-week trial. Lamotrigine was slowly titrated to an average endpoint dose of 160.7 ± 128.3 in subjects <12 years of age (N = 22) and 219.1 ± 172.2 mg/day in children 12–17 years of age (N = 17). Treatment with lamotrigine was associated with statistically significant levels of improvement in mean YMRS scores (−14.9 ± 9.7, P < 0.001) at endpoint. Lamotrigine treatment also resulted in significant improvement in the severity of depressive, attention-deficit/hyperactivity disorder (ADHD), and psychotic symptoms. Lamotrigine was generally well tolerated with marginal increase in body weight (47.0 ± 18.0 kg vs. 47.2 ± 17.9 kg, P= 0.6) and was not associated with abnormal changes in laboratory parameters. Several participants were discontinued due to skin rash; in all cases, the rash resolved shortly after discontinuation of treatment. No patient developed Steven Johnson syndrome. Conclusions: Open-label lamotrigine treatment appears to be beneficial in the treatment of bipolar disorder and associated conditions in children. Future placebo-controlled, double-blind studies are warranted to confirm these findings.
- Top of page
- Conflict of Interest
Despite ongoing controversy, pediatric bipolar disorder has gained acceptance in the clinical and research community as a valid clinical entity . It is thought to affect at least 1% of children and adolescents and is associated with high levels of morbidity and dysfunction [2,3]. Presentation of bipolar disorder in youth is predominantly characterized by mixed states with chronicity, complex cycling, and extremely poor functioning . Although early treatment of pediatric bipolar disorder could provide an enormous benefit to children, families, and society by alleviating the consequences associated with this chronic psychopathological state, not much is known about its treatment. As a consequence, these children are frequently treated with a multitude of medications with unclear efficacy and inadequate safety data .
Although in recent years, the atypical antipsychotics (risperidone, olanzapine, aripiprazole, and quetiapine) have been increasingly used in the treatment of adults and youth with bipolar disorder [6–12], these treatments have also been associated with substantial adverse effects especially weight gain, prolactinemia, glycemic dyscontrol, and dyslipidemia. This state of affairs calls for the further evaluation of additional safe and effective treatments for pediatric bipolar disorder.
Lamotrigine is a new generation antiepileptic drug, approved by the FDA in 2003 for the maintenance treatment of adults with bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, and mixed episodes) in patients treated for acute mood episodes with standard therapy. Recent studies have shown that lamotrigine maintenance treatment was more robust in bipolar depression among adults and that adults with rapid cycling respond to lamotrigine [13–18]. Lamotrigine monotherapy (50–200 mg daily) was also reported to be superior to placebo in the treatment of nonrapid cycling bipolar I depression in adults and uncontrolled observations have suggested possible antimanic [19,20], antidepressant , and anticycling/mood stabilization properties [13,19,22].
Although not adequately studied in pediatric bipolar disorder, the pharmacokinetics of lamotrigine in children and adolescents have been well studied via its antiepileptic indication. More is known about its safety and tolerability profile in the pediatric population than for many psychotropics currently used in standard clinical practice for the treatment of pediatric mood disorders.
Although serious dermatological reaction including Steven Johnson syndrome has been associated with lamotrigine treatment, clinician awareness, close scrutiny of subjects, and a slow titration rate have reduced the risk of serious rashes . However, lamotrigine has a low liability for metabolic syndrome and weight gain, which could offer the possibility of a better adverse effect profile than other mood stabilizing agents in which weight gain has been a problematic adverse event.
The main goal of this open label pilot study was to begin to address the safety, tolerability, and effectiveness of lamotrigine in the treatment of pediatric bipolar disorder. To this end, we conducted an exploratory, 12-week, open-label treatment, pilot study, of youth ages 6–17, who met the DSM-IV diagnostic criteria for bipolar I, bipolar II, or bipolar spectrum disorder. The study results will be used to generate hypotheses for a larger randomized controlled clinical trial. Based on the available literature in adults with bipolar disorder, we hypothesized that lamotrigine will be efficacious and well tolerated in youth with pediatric bipolar and bipolar spectrum disorders. To the best of our knowledge, this is the first study evaluating the antimanic effects of lamotrigine monotherapy in pediatric bipolar disorder.
- Top of page
- Conflict of Interest
All inclusion and exclusion criteria were assessed by clinical evaluation and all subjects had YMRS scores greater than 20. Fifty-one subjects were consented and assessed for eligibility for the study with 39 subjects being exposed to study medication (N = 7 did not meet entrance criteria and N = 5 withdrew consent). The 39 children enrolled in the study were 10.8 ± 2.9 years of age and predominantly male (61%, N = 24). Thirty-five (90%) of subjects met criteria for bipolar I disorder, one (2%) met criteria for bipolar II disorder, and three (8%) met criteria for BP-NOS. At study entry, the mean YMRS score was 31.6 ± 5.5. Of the 39 subjects enrolled, 22 (56%) completed the 12-week course; dropouts were due to adverse effects (N = 10), lack of efficacy (N = 2), noncompliance (N = 2), withdrawal of consent (N = 1), or difficulties in meeting the study schedule (N = 2). At study endpoint, the mean dose of lamotrigine was 160.7 ± 128.3 in subjects <12 years of age (N = 22) and 219.1 ± 172.2 mg/day in children 12–17 years of age (N = 17).
Figure 1 shows the adjusted weekly YMRS score. Mixed regression analysis demonstrated a statistically significant improvement from baseline within 1 week of treatment with further significant improvement over the next 12 weeks course (Figure 1). At endpoint, in LOCF analyses, the average reduction in YMRS score as −14.9 ± 9.7 points. Lamotrigine was also associated with a statistically significant improvement in symptoms of psychosis (BPRS: 41.0 ± 7.9 vs. 29.9 ± 9.2, P < 0.0001), depression (CDRS: 40.1 ± 12.9 vs. 31.8 ± 13.7, P= 0.0002), and ADHD (ADHD-RS: 35.6 ± 11.2 vs. 22.5 ± 15.7, P < 0.0001) from baseline to endpoint.
Figure 1. YMRS Scores in 39 subjects openly treated with lamotrigine over 12 weeks. Subjects were required to have a mean YMRS score of >20 at baseline to be enrolled. Remission from mania was defined as mean YMRS <12.
Download figure to PowerPoint
As shown in Figure 2, at study endpoint, 66% (N = 26) of subjects had a 30% reduction in baseline YMRS scores and 54% (N = 21) had a 50% reduction in baseline YMRS scores. 61% of subjects (N = 16) were rated on CGI-I as “much improved” or “very much improved” at study endpoint on the symptoms of mania and depression improved in 46% (N = 16) of subjects. Thus, 66% (N = 26) met our a priori criteria of response for acute mania; the CGI-I ≤2 or a 30% reduction in YMRS score. Using more stringent criteria to define remission we found that 43% of subjects (N = 17) had CDRS scores <28 and 36% (N = 14) of subjects had YMRS scores <12; and 26% (N = 10) were considered euthymic (YMRS <12 and CDRS <28) at endpoint (Figure 2).
Figure 2. Rate of response of mania and depression in 39 subjects openly treated with lamotrigine. CGI-I: CGI-lmprovement scale scored for mania and depression separately. Mania was assessed with the YMRS and depression with the CDRS. 30% and 50% change refer to changes in these ratings relative to baseline. Remission from mania or depression was defined at YMRS <12 or CDRS <28, respectively. Euthymia was defined as a YMRS <12 and a CDRS <28.
Download figure to PowerPoint
Metabolic parameters are presented in Table 1. With the exception of a small increase in posttreatment platelet count, plasma sodium, and plasma creatinine levels and a small decrease in QTc, there were no other abnormal laboratory or cardiovascular changes associated with treatment. There was no statistically significant or clinically significant increase in weight from baseline to endpoint (47.0 ± 18.0 kg vs. 47.2 ± 17.9 kg, P= 0.6). The most commonly reported adverse effects were gastrointestinal (GI) complaints, headache, cold symptoms, and dermatological effects (Fig. 3). Side effects reported as present at the last visit for subjects dropping due to adverse effects were (not mutually exclusive): dermatological (N = 7), GI complaints (N = 2), musculoskeletal (N = 1), headache (N = 3), and cold symptoms (N = 1).
Table 1. Baseline and endpoint metabolic results
| ||Baseline||Endpoint||F (1,38)||P-value|
|Pulse||85.8 ± 14.6||82.3 ± 11.7||1.3||0.3|
|Systolic blood pressure (mmHg)||108.5 ± 11.6||108.6 ± 10.9||<0.01||0.9|
|Diastolic blood pressure (mmHg)||62.4 ± 11.3||61.6 ± 11.4||0.1||0.7|
|PR interval||135.1 ± 17.4||138.1 ± 20.1||1.6||0.2|
|QRS interval||82.9 ± 7.8||82.4 ± 7.1||0.2||0.6|
|QTc interval||410.0 ± 12.6||403.9 ± 12.2||6.9||0.01|
|Sodium level||139.5 ± 1.5||140.4 ± 1.5||5.1||0.03|
|Potassium level||4.0. ± 0.3||4.1 ± 0.5||1.4||0.2|
|Chlorine level||103.3 ± 1.4||103.1 ± 1.8||0.2||0.7|
|Carbon dioxide level (mm/L)||26.2 ± 2.3||26.6 ± 2.4||1.1||0.3|
|Calcium level (mg/dL)||9.7 ± 0.3||9.7 ± 0.4||0.4||0.5|
|Urea nitrogen level||13.7 ± 3.0||12.7 ± 3.4||3.2||0.08|
|Creatinine level||0.72 ± 0.14||0.78 ± 0.18||9.1||0.005|
|Glucose level||84.8 ± 12.9||85.2 ± 10.4||0.02||0.9|
|SGPT (ALT)||19.2 ± 8.6||20.3 ± 12.3||0.4||0.5|
|SGOT (AST)||27.1 ± 6.4||28.4 ± 8.1||1.7||0.2|
|WBC||7.6 ± 1.8||7.6 ± 2.2||0.01||0.9|
|HCT||38.5 ± 2.8||39.1 ± 2.9||2.2||0.1|
|HGB||13.5 ± 1.1||13.7 ± 1.2||1.0||0.3|
|RBC||4.7 ± 0.4||4.8 ± 0.3||1.1||0.3|
|PLT||316.8 ± 55.5||339.9 ± 68.9||5.5||0.03|
|MCV||82.1 ± 5.7||82.6 ± 5.9||0.9||0.4|
|MCH||28.8 ± 2.3||28.8 ± 2.3||0.01||0.9|
|MCHC||35.0 ± 1.3||34.8 ± 1.1||0.9||0.4|
|RDW||13.2 ± 0.8||13.3 ± 0.9||0.1||0.7|
In all 15/39 subjects developed skin lesions at any point during the trial; 13/15 skin lesions were skin rashes and the remaining lesions were single cases of topical burn and chapped lips (Table 2). Six subjects developed mild rash of known etiology (contact dermatitis [N = 2], sunburn [N = 2], and dry skin [N = 2]), which resolved within a week of identification and these subjects successfully completed the trial. The remaining 7/13 subjects developed rash of unknown etiology; one developed mild petechiae in the abdominal region which resolved within a week without discontinuing the trial, and the remaining six discontinued the trial due to rash. Five of seven subjects with rash of unknown etiology developed rash within 6 weeks of exposure to lamotrigine ≤50 mg/day. All subjects that discontinued the trial developed maculo-papular rash (5/6) with the exception of one subject who developed multiple, pruritic, vescicular rash on the right side of the face. Maculo-papular rashes were multiple (in one case solitary), on the limbs (in two cases also on the trunk), pruritic (with the exception of one case), nonprogressive (except for one case) with mild–moderate severity and resolved within 1 week of discontinuation of lamotrigine. Among the subjects that discontinued the trial due to rash of unknown etiology, one subject was also receiving cephalexin for sore throat, an antibiotic with known adverse effect of skin rash, and in another case there was history of family member simultaneously developing similar rash. Notably, none of the participants in the trial developed serious rash (life-threatening or requiring hospitalization, Stevens Johnson syndrome, or erythema multiforme) or developed mucosal rash in conjunction with the skin rash.
Table 2. Dermatological adverse effects reported
|Subject (age/sex)||Trial status||Lamotrigine||Characteristics of skin lesion||Treatment|
|Exposure (weeks)||Dose (mg/day)||Number||Location||Pruritic||Severity||Description|
| 1461201 (13/M)||Dropped||5||50||Multiple||Face (right)||+||Moderate||Vesicular blochy red patches||Benadryl|
| 1462401 (9/F)||Dropped||9||140||Multiple||Arms, back||−||Mild||maculo-papular (erythematic)||−|
| 1463201 (7/F)||Dropped||3.5||15||Single||Neck||+||Moderate||Maculo-papular||Benadryl|
| 1463801 (17/F)||Dropped||4||50||Multiple||Arm, thighs||+||Moderate||Maculo-papular||Benadryl|
| 1463301 (12/M)||Dropped||8||200||Multiple||All limbs||+||Mild||Maculo-papular||−|
| 1464701 (7/M)||Dropped||5||35||Multiple||Arm, trunk (right)||+||Moderate||Maculo-papular||Benadryl|
| 1462601 (17/M)||Continued||4||50||Multiple||Abdomen||+||Mild||Petechiae||−|
| 1460601 (7/F)||Continued||8||200||Multiple||Truncal||−||Mild||Papular||−|
| 1460201 (10/M)||Continued||1||10||Multiple||Upper Extremity||−||Mild||No current skin lesion||−|
| 1463701 (12/F)||Continued||7||200||Multiple||Face||−||Mild||Skin irritation with discoloration||−|
| 1461501 (15/M)||Continued||1||25||Multiple||Limbs||+||Mild||Skin irritation with discoloration||−|
| 1464801 (9/F)||Continued||11||220||Single||Lips||−||Moderate||Chapped lips due to licking around lips||−|
| 1463901 (13/F)||Dropped*||4||50||Single||Face||−||Mild||Skin irritation without discoloration (dry skin)||−|
| 1461001 (8/F)||Continued||2||10||Single||Face|| ||Mild||Erythematous (dry skin)||−|
| 1460701 (7/F)||Droppeda||3||10||Single||Extremity||−||Mild||Topical burn||–|
- Top of page
- Conflict of Interest
This was a prospective, 12-week, open-label treatment trial of lamotrigine monotherapy in 39 youth with bipolar I, II, or bipolar not otherwise specified. Subjects participating in this study were young (10.8 ± 2.9 years) predominantly males (61%, N = 24) with bipolar I disorder experiencing significant symptoms of mania (YMRS 31.6 ± 5.5). Intent to treat analysis showed that subjects improved significantly from baseline to endpoint in symptoms of mania, depression, psychosis, and ADHD as measured by syndrome-specific rating scales and clinical global impression. Treatment with lamotrigine was generally tolerable with minimal impact on weight and metabolic parameters, but 25% of subjects discontinued the trial due to adverse effects. Although no participant developed Steven Johnson syndrome, dermatological adverse effects were common. These results suggest that lamotrigine monotherapy may be beneficial and well tolerated in the management of both mania and depression in children with BPD.
Our positive mood stabilizing effects associated with lamotrigine monotherapy are consistent with the only previous prospective open-label study of lamotrigine in the treatment of pediatric bipolar disorder by Chang et al. . This was an 8-week open-label trial of lamotrigine (mean final dose was 131.6 mg/day) in 20 adolescents (n = 19 completers) with diagnoses of bipolar disorder I, II, or not otherwise specified (30% of subjects were taking other psychotropic medications). At week 8, 84% responded and 58% were considered in remission. YMRS and Overt Aggression Scale-Modified scores also decreased significantly during the trial. There was no significant weight change, rash, or other adverse effects during the trial.
Our findings documenting significant antimanic effects associated with open-label treatment with lamotrigine are consistent with results observed in open-label studies of divalproex sodium. Kowatch et al. reported  response rates of 53% for divalproex sodium in a 6-week open label study and Pavaluri et al. (2005) reported significant antimanic effects associated with treatment with divalproex sodium in a 6-month open-label study of divalproex sodium in pediatric bipolar disorder . However, although an open-label study of divalproex sodium in pediatric bipolar disorder by Wagner et al. reported improvement in manic symptoms in its open-label phase, very few subjects improved sufficiently to be eligible to enter a planned double-blind discontinuation study following the open-label treatment . Likewise, while a 6-month open-label study of divalproex sodium extended release in the treatment of children and adolescents with acute mania by Redden et al. (226 subjects enrolled; 109 completed) reported improvement in manic symptoms, small improvements were seen in behavior and caregiver stress ratings and weight gain (16%), nausea (9%), increased appetite (8%), and elevations of mean ammonia levels in plasma were common . In contrast, a recently completed randomized clinical trial of divalproex sodium extended release in the treatment of children and adolescents with bipolar disorder failed to show separation from placebo . Very modest effects also observed in open-label studies of carbamazepine immediate (CBZ-IR)  and extended (CBZ-ER) release formulations  and in a controlled clinical trial oxcarbazepine failed to show separation from placebo .
The observed antidepressant effects associated with lamotrigine treatment in the present pediatric trial is consistent with the substantial evidence available from previous controlled trials in adults indicating that lamotrigine may be efficacious in improving the depressive symptoms of mixed episodes in adult populations with BPD [41,42]. They are also consistent with findings reported by Chang et al.  documenting clinical and significant decreases in ratings of depression in eight adolescents with bipolar disorder following 8 weeks of treatment with lamotrigine that were correlated with amygdalar activation using f-MRI . They are also consistent with retrospective findings reported by Soutullo et al.  in a small sample of Spanish adolescents with bipolar spectrum depression. Considering the manicogenic potential of antidepressants in the management of bipolar youth, if confirmed in larger controlled trials, these findings would support the use of lamotrigine in the management of both the manic, depressed, and the mixed manic states  that characterize juvenile bipolar disorder .
Equally noteworthy is the observation that treatment with lamotrigine was associated with improvement across other domains of comorbid psychopathology measured by the BPRS and the ADHD rating scale. Considering that psychotic features are commonly associated with pediatric bipolar disorder, if confirmed in larger randomized clinical trials, this finding would suggest that treatment with lamotrigine monotherapy could be adequate in the management of bipolar youth with and without comorbid psychosis. Likewise, considering the very high rates of ADHD comorbidity in pediatric bipolar disorder [47,48] and the potential manicogenic effect of stimulant drugs [49–51], if confirmed in larger randomized clinical trials, this finding would suggest that lamotrigine monotherapy could help manage both the bipolar as well as the ADHD symptomatology in some youth with bipolar disorder. More work is needed to determine if the improvement in these comorbid domains is attributable to the lamotrigine specifically or if the symptomatic improvement is secondary to mood stabilization.
For the majority of subjects in our study, treatment with lamotrigine was well tolerated at the mean dose of 160.7 ± 128.3 in subjects <12 years of age (N = 22) and 219.1 ± 172.2 mg/day in adolescents. There were no serious adverse effects. Of the 39 subjects enrolled, 22 (56%) completed the 12-week course. Of those that dropped out, 10 did so due to adverse effects. In general, most adverse effects were considered mild or moderate. Cardiovascular parameters including blood pressure, heart rate, and ECG values following treatment with lamotrigine were within normal limits. Mean values of all safety laboratory tests including glucose and lipid parameters remained within normal limits throughout the trial. It is particularly noteworthy that in this acute treatment with lamotrigine, weight gain was minimal.
Although skin rashes were relatively common, none of the participants in the trial developed a serious rash (life-threatening, requiring hospitalization, Stevens Johnson syndrome or erythema multiforme). In all, 39% (15/39) of the youth developed skin lesion at some point during the trial. Of these, six discontinued the trial due to the rash. With the exception of one of these six subjects who developed multiple, pruritic, vescicular rash on the right side of the face, the other five subjects developed a nonprogressive maculo-papular rash. The rash developed within 6 weeks of exposure to lamotrigine at doses of ≤50 mg/day in 67% (4/6) of the youth that discontinued lamotrigine trial due to rash. In all cases, the rash resolved promptly (within a week) after discontinuation of lamotrigine.
The results of this study need to be considered in light of some methodological limitations. This was an open study; therefore, the assessments were not blind to treatment. We also did not employ a placebo-control group and, therefore, cannot separate the effects of treatment from time. We also included subjects with bipolar spectrum disorders not with a sample size needed to stratify subjects based upon diagnostic category. Concomitant pharmacotherapy (with the exception of mood stabilizers, anticonvulsants, neuroleptics, and antidepressants) or psychotherapy were allowed during the study if these treatments were in place at baseline and were not modified during the 12-week open-label trial. There were insufficient number of subjects receiving any particular pharmacotherapy to estimate the impact of concomitant treatment on the clinical response presented here; we did not systematically collect information regarding concomitant psychotherapy. Although reports of adverse effects were common in our data, our assessment of adverse effects relied exclusively on spontaneous reports by subjects and their parents.
Despite these considerations, this open-label trial of lamotrigine monotherapy showed that acute treatment with lamotrigine was associated with antimanic, antidepressant, antipsychotic, and anti-ADHD responses in children and adolescents with bipolar and bipolar spectrum disorder. In this short-term trial, treatment with lamotrigine monotherapy was relatively well tolerated. Although no child developed Steven Johnson syndrome, skin rashes were relatively common despite the slow titration rate. Despite these encouraging results, firmer conclusions regarding the safety and efficacy of lamotrigine in the treatment of pediatric bipolar disorder await results from larger and controlled clinical trials.
Conflict of Interest
- Top of page
- Conflict of Interest
Dr. Joseph Biederman is currently receiving research support from the following sources: Alza, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merck, Organon, Otsuka, Shire, NIMH, and NICHD. In 2009, Dr. Joseph Biederman received a speaker's fee from the following sources: Fundacion Areces, Medice. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Janssen, McNeil, NARSAD, NIDA, New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc. and Wyeth.
Dr. Gagan Joshi discloses the following potential conflicts of interest: Ethel DuPont Warren Fellowship Award 2005–6, a Pilot Research Award from the American Academy of Child and Adolescent Psychiatry 2005, McNeil Pediatrics (CME sponsored by SynerMed Communications), Bristol Myers Squibb (Site PI for Multi-centered Trial), Glaxo Smith Kline (Site PI for Multi-centered Trial), and Shire (Member of national advisory board). Dr. Gagan Joshi is a subinvestigator for clinical trials sponsored by Shire, Johnson & Johnson, Pfizer, Merck, Cephlon, McNeil, Eli-Lily, Abbott, Novartis, Bristol Myers Squibb, Organon, Otsuka, Takeda, and New River Pharmaceuticals.
Dr. Eric Mick receives research support from the following sources and is on an advisory board for the following sources: McNeil Pediatrics, Ortho-McNeil Janssen Scientific Affairs, Pfizer, Shire Pharmaceuticals, and the National Institute of Mental Health (NIMH) and has had an advisory or consulting relationship with Pfizer and Shire Pharmaceutical.
Dr. Robert Doyle discloses the following potential conflicts of interest: Shire, Lilly, Novartis, McNeil, Janssen, Bristol Myers Squibb, Elan, Celltech, NEI, Phase V, CME Outfitters, PriMed, Effikacy, Danemiller Foundation.
Dr. Georgiopoulos received an unrestricted educational grant for a 2005 book from GlaxoSmithKline. She received an honorarium for a Continuing Medical Education presentation from Pri-Med/Physicians Academy for Clinical and Management Excellence, supported by an educational grant from McNeil Pediatrics, administered by Ortho-McNeil Janssen Scientific Affairs. She has participated as Sub-Investigator or Co-Investigator on research studies funded by the following: Bristol Myers Squibb Research Institute, Cephalon, Eli-Lilly & Co., GlaxoSmithKline, McNeil Consumer and Specialty Pharmaceuticals, Novartis Pharmaceuticals Corporation, Shire Development/Shire Pharmaceuticals; as well as NIH-NIMH, NIH-NIDA, NARSAD, the Stanley Foundation, and Harvard Medical School/Massachusetts General Hospital.
Dr. Hammerness has been a speaker for, received research funds or participated in CME activities/professional talks supported by the following pharmaceutical companies: Abbott, Eli Lilly & Company, Forest Research Institute, Ortho-McNeil-Janssen, and Shire. Dr. Hammerness has also received research funds from Elminda Ltd. Dr. Hammerness has also participated, as an investigator, in research studies in the past 2 years funded by the following pharmaceutical companies: Bristol Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, New River, Novartis, Organon, Otsuka, Pfizer, Shire, Takeda. Dr. Hammerness has also received honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy are supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supporting programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's website, http://www.mghcme.org.
Meghan Kotarski, MBA, has no conflict of interest to disclose.
Courtney Willams, BA, has no conflict of interest to disclose.
Janet Wozniak, MD, is the Author of “Is Your Child Bipolar” published May 2008, Bantam Books. Dr. Wozniak is a speaker for McNeil, Primedia/MGH Psychiatry Academy, and is on the Speakers Bureau for Lilly. Dr. Wozniak is on the Advisory Board/Consulting for Pfizer and Shire. Dr. Wozniak receives research support for McNeil, Shire, and Lilly. Dr. Wozniak's spouse, John Winkelman, MD, PhD, is on the Speakers Bureau for Boehringer-Ingelheim, Cephalon, GlaxoSmithKline, King, Sanofi-Aventis, Sepracor, and Takeda, is on the Advisory Board/Consulting for Axon Labs, Boehringer-Ingelheim, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis, Neurogen, Novadel Pharma, Pfizer, UCB (Schwarz) Pharma, Sanofi-Aventis, Sepracor, and Takeda, and receives research support from Boehringer-Ingelheim, GlaxoSmithKline, UCB (Schwarz) Pharma, Pizer, and Sepracor.
The Kimmerly-Neal Fund for the Study of Cognition and Psychiatric Disorders in Children and the Pediatric Psychopharmacology Council Fund.